Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide for GI Bleeding in HHT and Angiodysplasia
NCT02287558Phase 1Completed
- Sponsor
- Cleveland Clinic
- Start
- Jan 2015
- Primary completion
- Jun 2019
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pomalidomide in hereditary hemorrhagic telangiectasia (HHT) and gastric antral vascular ectasia (GAVE), sponsored by Cleveland Clinic. Primary endpoint: Transfusion requirement measure at 8 months. Started Jan 2015; status: completed.
02
Drugs
pomalidomide
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)gastric antral vascular ectasia (GAVE)
Beyond the preview
Go deeper on NCT02287558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02287558.